A detailed history of Avoro Capital Advisors LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 2,622,222 shares of KRYS stock, worth $416 Million. This represents 7.18% of its overall portfolio holdings.

Number of Shares
2,622,222
Previous 2,433,000 7.78%
Holding current value
$416 Million
Previous $447 Million 6.73%
% of portfolio
7.18%
Previous 6.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$174.7 - $213.66 $33.1 Million - $40.4 Million
189,222 Added 7.78%
2,622,222 $477 Million
Q2 2024

Aug 14, 2024

SELL
$153.12 - $183.64 $18.8 Million - $22.5 Million
-122,555 Reduced 4.8%
2,433,000 $447 Million
Q1 2024

May 15, 2024

SELL
$108.01 - $179.35 $1.08 Million - $1.79 Million
-10,000 Reduced 0.39%
2,555,555 $455 Million
Q3 2023

Nov 14, 2023

BUY
$108.51 - $130.22 $514,771 - $617,763
4,744 Added 0.19%
2,565,555 $298 Million
Q2 2023

Aug 14, 2023

BUY
$78.48 - $130.32 $63.6 Million - $106 Million
810,811 Added 46.33%
2,560,811 $301 Million
Q1 2023

May 15, 2023

BUY
$72.39 - $84.27 $24.6 Million - $28.7 Million
340,000 Added 24.11%
1,750,000 $140 Million
Q4 2022

Feb 14, 2023

BUY
$63.14 - $79.9 $8.52 Million - $10.8 Million
135,000 Added 10.59%
1,410,000 $112 Million
Q3 2022

Nov 14, 2022

BUY
$64.85 - $82.4 $13 Million - $16.5 Million
200,000 Added 18.6%
1,275,000 $88.9 Million
Q2 2022

Aug 15, 2022

BUY
$48.93 - $73.47 $3.43 Million - $5.14 Million
70,000 Added 6.97%
1,075,000 $70.6 Million
Q1 2022

May 16, 2022

BUY
$51.99 - $72.11 $27.6 Million - $38.2 Million
530,000 Added 111.58%
1,005,000 $66.9 Million
Q4 2021

Feb 14, 2022

BUY
$39.81 - $88.24 $18.9 Million - $41.9 Million
475,000 New
475,000 $33.2 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.07B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.